Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of Humalutin, a chimeric anti-CD37 Antibody Radionuclide Conjugate (ARC) in Non-Hodgkin's-lymphoma.

Trial Profile

A Phase 1 study of Humalutin, a chimeric anti-CD37 Antibody Radionuclide Conjugate (ARC) in Non-Hodgkin's-lymphoma.

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chimeric-anti-CD37-Antibody-Radionuclide-Conjugate (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2018 According to a Nordic Nanovector media release, due to the revised timelines for the company's PARADIGME study and the need to conserve cash until it's data read-out, company has decided to put this phase 1 study on hold.
    • 04 Apr 2018 Status changed from planning to suspended, according to a Nordic Nanovector media release.
    • 15 Mar 2018 According to a Nordic Nanovector media release, the trial is expected to begin in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top